Please assess the completion status of the following clinical trial:

Trial Title: Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatient or outpatient hematology patient receiving one of the following regimens:~* Chemotherapy for hematologic malignancy:~* ABVD~* ICE ± R~* 7+3~* Conditioning therapy for stem cell transplantation:~* BEAM~* Bu/Cy ± ATG~* Bu/Flu ± ATG~* FluCy ± ATG~* FluCy + TBI~* BuMel~* FluBuCy~* Melphalan~* Etoposide + TBI~* Cyclophosphamide + TBI~Exclusion Criteria:~* Allergy to olanzapine~* Documented nausea or vomiting ≤24 hours prior to enrollment~* Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to enrollment or planned during protocol therapy~* Chronic alcoholism~* Pregnant~* Declined or unable to provide an informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triplet Therapy Plus Placebo (Type: PLACEBO_COMPARATOR): All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
- Triplet Therapy Plus Olanzapine (Type: ACTIVE_COMPARATOR): All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).